Summary of COVID-19 ravulizumab studies
Studies
Meta Analysis
Hide extended summaries
RCT 201 mechanically ventilated patients with severe COVID-19 showing no significant difference in mortality with ravulizumab. The study was terminated early due to futility.
Mar 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023000826, https://c19p.org/annane
280 patient ravulizumab late treatment RCT: 1% lower mortality (p=0.98), 53% higher progression (p=0.13), 24% higher need for oxygen therapy (p=0.57), and 3% lower hospital discharge (p=0.86).
RCT 417 hospitalized COVID-19 patients in the UK showing no significant difference in a composite primary endpoint (time to death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure) with baricitinib or ravulizumab. The trial was stopped early due to futility. There were no significant differences in secondary outcomes including disease severity, days to discharge, mortality, or adverse events.
Dec 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023003764, https://c19p.org/hall3
1. Annane et al., Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial
201 patient ravulizumab ICU RCT: 8% higher mortality (p=0.76).RCT 201 mechanically ventilated patients with severe COVID-19 showing no significant difference in mortality with ravulizumab. The study was terminated early due to futility.
Mar 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023000826, https://c19p.org/annane
280 patient ravulizumab late treatment RCT: 1% lower mortality (p=0.98), 53% higher progression (p=0.13), 24% higher need for oxygen therapy (p=0.57), and 3% lower hospital discharge (p=0.86).
RCT 417 hospitalized COVID-19 patients in the UK showing no significant difference in a composite primary endpoint (time to death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure) with baricitinib or ravulizumab. The trial was stopped early due to futility. There were no significant differences in secondary outcomes including disease severity, days to discharge, mortality, or adverse events.
Dec 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023003764, https://c19p.org/hall3
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.